Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 11/20 | 0.58 |
| ▸ | TP53 | P04637 | 9/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22680753 | 0.86 | LMNA (0.58) | ALDH1A1KDM4ELMNATP53MAPT | |
| SCHEMBL902276 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNATP53MAPT | |
| SCHEMBL902805 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KDM4ELMNATP53MAPT | |
| SCHEMBL902218 | 0.83 | LMNA (0.71) | ALDH1A1KDM4ELMNATP53MAPT | |
| SCHEMBL15262396 | 0.82 | HSD17B10 (0.66) | ALDH1A1KDM4ELMNATP53MAPT | |
| SCHEMBL12156081 | 0.81 | TP53 (0.64) | ALDH1A1KDM4ELMNATP53MAPT | |
| SCHEMBL902627 | 0.80 | LMNA (0.63) | ALDH1A1KDM4ELMNATP53MAPT | |
| SCHEMBL902473 | 0.79 | HSD17B10 (0.57) | ALDH1A1KDM4ELMNATP53MAPT | |
| SCHEMBL902171 | 0.79 | LMNA (0.66) | ALDH1A1KDM4ELMNATP53MAPT | |
| SCHEMBL15572020 | 0.78 | LMNA (0.76) | ALDH1A1KDM4ELMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360381-A1 | COMPOUNDS FOR TREATING DENGUE VIRUS INFECTION AND OTHER VIRAL INFECTIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360381-A1 | COMPOUNDS FOR TREATING DENGUE VIRUS INFECTION AND OTHER VIRAL INFECTIONS | F3, CD4, F12 | ALDH1A1 3098/4885KDM4E 3315/4885LMNA 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.